Brain Trials

A list of our early phase brain cancer trials which are open to recruitment at University College London Hospitals.

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked IRAS Number, which will take you to the UCLH Find a Study database.

CITADEL-123

A Phase I clinical trial to assess the activity of I-123 Poly Adenosine Diphosphate Ribose Polymerase I inhibitor (123I-ATT001) directly administered in subjects with relapsed glioblastoma

IRAS Number:1006521
Principal Investigator:Dr Paul Mulholland
Drug Class/ Treatment:

123I-ATT001 (I-123 Poly Adenosine Diphosphate Ribose Polymerase I inhibitor)

Intracavitary instillation

Patient Population:Relapsed Glioblastoma
Trial Hosted By - UCLH Clinical Research Facility (CRF)

LOXO-RET-18036

A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumours 

IRAS Number:306043
Principal Investigator

Dr Sara Stoneham

Drug Class/ Treatment:

Selpercatinib (LOXO-292) (RET Inhibitor)

Patient Population:

Paediatric patients ≥ 6 months of age and ≤ 21 years of age at Cycle 1 Day 1 (C1D1)

  • RET fusion-positive solid tumor with measurable disease
  • RET-mutant MTC with measurable disease
  • RET fusion-positive primary CNS tumor with measurable disease.

Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

Principal Investigator(s)